The AML Landscape: Present and Future video
Speaker: Dr Eleni Tholouli
Dr. Eleni Tholouli is a Consultant Haematologist at Manchester University NHS Trust and Director of the Adult Stem Cell Transplant Unit. She is a member of the Haemato-Oncology Pathway Board at Manchester Cancer and of national bodies such as the AML Working Group and the Blood and Marrow Transplantation Clinical Reference Group. Her expertise covers a wide range of haemato-oncological malignancies and non-malignant disorders.
In this video, Dr. Thoulouli discusses Mylotarg™ NICE approval and its practical approach to the issue of waiting for cytogenics and Mylotarg’s use1. She also mentions results in event free survival and relapse risk alongside the safety data2. Practical considerations using the ALFA schedule, platelet recovery, risk of VOD and minimising risks to the liver are also considered2.
1. NICE Technology Appraisal Guidance (TA545). Gemtuzumab ozogamicin for untreated acute myeloid leukaemia. Available at: https://www.nice.org.uk/guidance/TA545/history. Published: 14 November 2018. Accessed: October 2019.
2. MYLOTARG Summary of Product Characteristics. Available at: https://www.medicines.org.uk/emc/product/9151/smpc. Accessed: October 2019.
PP-MYL-GBR-0160. December 2019